PURE Bioscience, Inc. (OTCQB: PURE) is focused on developing and commercializing our proprietary antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented, stabilized ionic silver, and our initial products contain Silver Dihydrogen Citrate (SDC), according to the company’s website (see here: www.PureBio.com). SNNLive caught up with Hank Lambert, CEO of PURE Bioscience, Inc. at the Marcum MicroCap Conference 2016 in New York City, NY.
In this video interview, Mr. Lambert and our host discuss the following topics:
- Overview of PURE Bioscience, Inc.
- Discusses FDA Approval for their technology and how that has affected the company
- First-mover advantage and barriers to entry
- Milestones for 2016-2017
For more information about PURE Bioscience, Inc., please visit: www.PureBio.com
The interview may contain forward-looking statements about PURE Bioscience, Inc. See PURE Bioscience's periodic filings with the Securities and Exchange Commission for more complete information.
© 2017 Stock News Now
Supported by Superior Web Solutions